Richard Furie, MD, is chief, division of rheumatology, at Northwell Health, and professor of medicine at Hofstra/Northwell School of Medicine. Join us in this ACR interview, as we discuss the story of interferon, lupus therapeutics — including B cell depletion — and the future of lupus research and treatments.

• Intro :10

• Background on Dr. Furie :16
• The interview :56
• • What advancements in the pathophysiology of lupus are you most excited about? 1:10
  • The interferon story 1:23
  • • The interferon story is not finished yet 7:18
    • Dendritic cells in lupus patients 7:41
    • What is “interferon signature?” 8:07
    • Do we see different clinical phenotype in patients with high interferon signature? 9:38
  • What’s your opinion on the role of B cells? 10:07
  • • Any other pathophysiology mechanisms being used to target B cells? 13:15
  • Are we stretched thin in terms of number of lupus patients in trials? 15:21
  • • How would designating lupus as an orphan disease change the way it’s investigated? 16:40
    • What is your main concern regarding study design? 17:37
  • Looking 10 years ahead, do you think what we call “lupus” will still be referred to as such, or will it be decompartmentalized into different diseases? 21:26
  • What’s the expense of cytokine profiling? 22:40
  • What excites you the most about the future of lupus research? 23:21
• Thank you, Dr. Furie 24:41
• Recap 24:43
• Shout out to the 7th Annual Basic and Clinical Immunology for the Busy Clinician: What is New and Hot in Immunology bootcamp in Scottsdale, AZ, Feb. 15-16, 2019 25:31

We’d love to hear from you! Send your comments/questions to [email protected]. And be sure to follow us on Twitter @AdamJBrownMD and @HealioRheum.

This information is brought to you by Healio and is not sponsored by, nor a part of, the American College of Rheumatology.